<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481728</url>
  </required_header>
  <id_info>
    <org_study_id>A6121189</org_study_id>
    <nct_id>NCT00481728</nct_id>
  </id_info>
  <brief_title>Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.</brief_title>
  <official_title>Evaluation of Sympathetic Skin Responses and Heart Rate Variability as Objective Measures of Bladder Sensation - a Double Blind Third Party Open Placebo Controlled Randomised Study Using a Single Dose of Tolterodine in Patients With Idiopathic Overactive Bladder and Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      Measuring sympathetic skin response or heart rate variability can provide an objective
      biomarker of bladder sensation and its modulation by drug with potential to treat overactive
      bladder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of the link between bladder sensation and changes in skin electrical conductance
      and heart rate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate variability evoked by filling cystometry and intravesical neurostimulation and sympathetic skin response evoked by intravesical neurostimulation in healthy volunteers and OAB patients</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the correlation between the changes in heart rate variability and sympathetic skin response evoked by filling cystometry and intravesical neurostimulation in OAB patients.</measure>
    <time_frame>duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine whether there is a difference in the stimulus response relationship for the evoked changes in HRV and SSR between healthy volunteers and OAB patients.</measure>
    <time_frame>duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Tolterodine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine</intervention_name>
    <description>Single dose per patient as determined by protocol.</description>
    <arm_group_label>Tolterodine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Filling cystometry</intervention_name>
    <description>This is a procedure.</description>
    <arm_group_label>Tolterodine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravesical neurostimulation</intervention_name>
    <description>This is a procedure.</description>
    <arm_group_label>Tolterodine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, healthy volunteers or OAB patients 18-65 years old, non pregnant and non
             lactating

        Exclusion Criteria:

          -  History of lower urinary tract pathology

          -  Excessive alcohol and tobacco consumption

          -  Treatment with investigational drug in the last 30 days

          -  Abnormal ECG trace

          -  Conditions that would contraindicate the use of tolterodine or any other anti
             muscarinic agent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zurich</city>
        <zip>CH- 8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6121189&amp;StudyName=Evaluation%20of%20the%20link%20between%20bladder%20sensation%20and%20changes%20in%20skin%20electrical%20conductance%20and%20heart%20rate.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2007</study_first_submitted>
  <study_first_submitted_qc>June 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2007</study_first_posted>
  <last_update_submitted>May 27, 2009</last_update_submitted>
  <last_update_submitted_qc>May 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

